Literature DB >> 14713751

Epidemiology of inflammation and prostate cancer.

Elizabeth A Platz1, Angelo M De Marzo.   

Abstract

PURPOSE: We provide an overview of some of the basic, clinical and epidemiological research that has been conducted to investigate the potential role of chronic inflammation in prostate carcinogenesis and to provide direction for future research on this hypothesis.
MATERIALS AND METHODS: We reviewed the literature on this topic.
RESULTS: Chronic inflammation has long been linked to cancers with an infectious etiology, such as stomach, liver and colon cancer, in patients with inflammatory bowel disease. Whether intraprostatic inflammation contributes to prostate carcinogenesis is unknown. Inflammation is frequently present in prostate biopsies, radical prostatectomy specimens and tissue resected for treatment of benign prostatic hyperplasia. Also, inflammatory infiltrates are often found in and around foci of atrophy that are characterized by an increased proliferative index. These foci, called proliferative inflammatory atrophy, may be precursors of early prostate cancer or may indicate an intraprostatic environment favorable to cancer development. Epidemiological studies have indirectly examined the role of chronic inflammation in prostate carcinogenesis through studies of pro-inflammatory and anti-inflammatory factors. When taken together studies of sexually transmitted infections, clinical prostatitis, and genetic and circulating markers of inflammation and response to infection hint at a link between chronic intraprostatic inflammation and prostate cancer.
CONCLUSIONS: Additional well-designed basic, clinical and epidemiological studies are needed to resolve questions about the role of chronic inflammation in prostate carcinogenesis and to determine if intraprostatic inflammation is a rational target for chemoprevention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14713751     DOI: 10.1097/01.ju.0000108131.43160.77

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  74 in total

1.  Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial.

Authors:  Theodore M Brasky; Cathee Till; Emily White; Marian L Neuhouser; Xiaoling Song; Phyllis Goodman; Ian M Thompson; Irena B King; Demetrius Albanes; Alan R Kristal
Journal:  Am J Epidemiol       Date:  2011-04-24       Impact factor: 4.897

Review 2.  Nuclear morphometry, nucleomics and prostate cancer progression.

Authors:  Robert W Veltri; Christhunesa S Christudass; Sumit Isharwal
Journal:  Asian J Androl       Date:  2012-04-16       Impact factor: 3.285

3.  Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer.

Authors:  Sabina Davidsson; Michelangelo Fiorentino; Ove Andrén; Fang Fang; Lorelei A Mucci; Eberhard Varenhorst; Katja Fall; Jennifer R Rider
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-27       Impact factor: 4.254

Review 4.  Altered metabolism and mitochondrial genome in prostate cancer.

Authors:  G D Dakubo; R L Parr; L C Costello; R B Franklin; R E Thayer
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

5.  [Chronic inflammation as promotor and treatment target in benign prostate hyperplasia (BPH) and in prostate cancer].

Authors:  G Kramer; D Mitteregger; A Maj-Hes; S Sevchenco; W Brozek
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

6.  Association of Toll-like receptor (TLR) 2, 3 and 9 genes polymorphism with prostate cancer risk in North Indian population.

Authors:  Raju K Mandal; Ginu P George; Rama D Mittal
Journal:  Mol Biol Rep       Date:  2012-02-06       Impact factor: 2.316

Review 7.  Risk factors for prostate cancer.

Authors:  Amit R Patel; Eric A Klein
Journal:  Nat Clin Pract Urol       Date:  2009-02

8.  Prediagnostic Body Mass Index Trajectories in Relation to Prostate Cancer Incidence and Mortality in the PLCO Cancer Screening Trial.

Authors:  Scott P Kelly; Barry I Graubard; Gabriella Andreotti; Naji Younes; Sean D Cleary; Michael B Cook
Journal:  J Natl Cancer Inst       Date:  2016-10-20       Impact factor: 13.506

9.  Biological mediators of effect of diet and stress reduction on prostate cancer.

Authors:  Gordon A Saxe; Jacqueline M Major; Lindsey Westerberg; Srikrishna Khandrika; Tracy M Downs
Journal:  Integr Cancer Ther       Date:  2008-09       Impact factor: 3.279

10.  ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity.

Authors:  Feng Jin; Shazia Irshad; Wei Yu; Madesh Belakavadi; Marina Chekmareva; Michael M Ittmann; Cory Abate-Shen; Joseph D Fondell
Journal:  Mol Cancer Res       Date:  2013-03-28       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.